Featured
Status
Search Clinical Trials
Completed
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases (External Link)
CAMPATH-1H will be given as a daily IV infusion for three days. Fludarabine will be given as a daily IV infusion for four days. Anti-CD45 will be given as a …
Baylor Role:
Lead Sponsor
Terminated
Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases (External Link)
Fludarabine will be given as a daily IV (intravenous, by vein) infusion for a total of 5 days. CAMPATH-1H will be given as a daily 4-hour IV (intravenous, by vein) …
Baylor Role:
Lead Sponsor
Completed
Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease (External Link)
Subjects will receive the chemotherapy through a plastic tube (catheter) placed into a vein under the collarbone. The antibody rituximab is given on the day of admission. The subject will …
Baylor Role:
Lead Sponsor
Terminated
Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT (External Link)
Patients will have received a haplo-identical stem cell transplant on our on-going study "CD45 (YTH-24 and YTH-54) and CD52 (Campath 1H) Monoclonal Antibody Conditioning Regimen for Allogeneic Donor Stem Cell …
Baylor Role:
Lead Sponsor
Terminated
Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia (External Link)
Before patients receive any treatments, they will have the following: - Complete history and physical exam - Dental consultation - Bone marrow aspirate - Blood tests - Urinanalysis - Tests …
Baylor Role:
Lead Sponsor
Terminated
Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (External Link)
We expect that the patient's participation in this study will last approximately 18 months to 2 years. Before treatment begins, they will be evaluated to confirm they meet the requirements …
Baylor Role:
Lead Sponsor
Completed
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL (External Link)
After subjects have completed the pretreatment evaluations, they will receive an injection of Enbrel - the study drug -(given under the skin) twice weekly. If the subjects disease stabilizes or …
Baylor Role:
Lead Sponsor
Terminated
Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia (External Link)
If clinically feasible (no aplasia, no active malignancy), the recipients marrow will be harvested and cryopreserved as a back up for use if non-engraftment/rejection is followed by failure to undergo …
Baylor Role:
Lead Sponsor
Terminated
Stem Cell Transplantation for Patients With Graft Failure Following an Allogeneic Transplant, Using Identical or Near Identical Donors and Less Toxic Conditioning With CAMPATH 1H (External Link)
Study participants will receive the following treatment: Day -5 to -2...Fludarabine 30mg/m2* and CAMPATH** 1H 10mg IV Day -1.........Day of rest Day 0..........Stem cell transplant (infusion) Where possible, patients will …
Baylor Role:
Lead Sponsor
Terminated
Stem Cell Transplant for Hematologic Diseases (External Link)
Before treatment begins, stem cells will be collected from the donor's blood or bone marrow. The stem cells will be collected and frozen before we start to give the patient …
Baylor Role:
Lead Sponsor